Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Pomegranate juice may soothe gut inflammation in colitis patients

NCT ID NCT07115862

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study is testing whether drinking 8 ounces of pomegranate juice daily for 8 weeks can reduce gut inflammation and improve quality of life in people with mild-to-moderate ulcerative colitis. Researchers will also look at how the juice affects gut bacteria. The study involves 30 adults who follow a low-fiber diet and will compare the juice period to a no-juice period.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pomegranate juice
What this could lead to
If it works, this could point toward a simple dietary supplement to help manage ulcerative colitis symptoms and reduce inflammation.
What could go wrong
This is a very small pilot study with only 30 participants, so results may not apply to everyone. It also relies on self-reported symptoms and may not show clear benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Adults ≥ 18 yo * Following a low-polyphenol and fiber diet (\< 3 servings of fruits/vegetables per day) * Mild-to-moderate UC at the time of screening (2 ≤ partial Mayo scores ≤ 5) * Supportive evidence of active inflammation (hsCRP \>1 mg/L, fecal calprotectin \>50 µg/g stool, or abnormal lower endoscopy) in individuals with biopsy-proven UC * Patients on 5-aminosalicylates must be on a stable dose for ≥ 4 weeks prior to screening * Patients on treatment with immunosuppressive therapy (e.g., azathioprine/6-mercaptopurine, methotrexate) must be on stable dose for 8 weeks prior to baseline visit * At the time of baseline visit, patients may be on no more than 20 mg/day of prednisone and 9 mg/day of budesonide MMX * Subjects must read and sign the Institutional Review Board-approved written informed consent prior to the initiation of any study specific procedures or enrollment. A subject will be excluded for any condition that might compromise the ability to give truly informed consent. Exclusion Criteria: * • Non-English speaker * Vegetarian/vegan * Known pomegranate allergy * Documented chronic disease besides UC, including diabetes, renal or liver diseases, metabolic syndrome, active cancer, MI or stroke, history of gastric bypass * Patients with CD, indeterminate/severe to fulminant colitis * History of colectomy or colonic dysplasia * Presence of ileal pouch or ostomy * Evidence of active bacterial or viral gastroenteritis as indicated by positive stool studies for ova \& parasites, Clostridium difficile, and stool culture * Recent hospitalizations (within 2 weeks of screening) for UC requiring IV steroids * Presence of the following labs indicative of severe colitis: a. Hemoglobin \< 8.0 g/dl b. Albumin \< 3.0 g/dl * Recent systemic antibiotics use (within 3 months of screening) or active use of anti-diarrheal medications * Taking supplements known to affect metabolism or gut microbiota composition (probiotics, fiber, etc.), unless willing to stop for the study duration * Use of Total Parenteral Nutrition (TPN) * Use of cyclosporine, tacrolimus, or thalidomide within 2 months prior to screening * Taking exogenous hormones (e.g., hormone replacement therapy) * Recent weight fluctuations (\>10% in the last 6 months) * Smoker or living with a smoker * Use of \>20 g of alcohol per day * Unable or unwilling to comply with the study protocol (including unwillingness to avoid watermelon and other lycopene-rich foods for the whole duration of the study) * Unable to provide consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ulcerative colitis (disorder) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UCLA Center for Human Nutrition

    RECRUITING

    Los Angeles, California, 90095, United States

  • West Los Angeles VA Medical Center

    NOT_YET_RECRUITING

    Los Angeles, California, 90073, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.